Literature DB >> 20213607

Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy?

Claudio Ponticelli1, Patrizia Passerini.   

Abstract

Idiopathic membranous nephropathy (IMN) may have a variable course, with some patients entering spontaneous remission and others slowly progressing to renal failure. The disease is treatable, but the available treatments are not devoid of potential morbidity. We review the studies dedicated to finding prognostic markers. Although a number of clinical and histologic markers are associated with an increased risk of progression to renal failure, in many cases it is still impossible to recognize at presentation what will be the long-term outcome for a patient with IMN. More reliable are time-dependent predictors, such as the amount of proteinuria over time and complete or partial remission. However, this means that a physician should wait for months or even years before taking therapeutic decisions, with the risk of starting after renal or extrarenal complications have already developed. How to proceed will have to be dictated by a careful evaluation of the patient: Taking into consideration not only the risk of renal progression but also the possible extrarenal complications, we suggest starting a "specific" treatment for patients presenting with full-blown nephrotic syndrome or with increasing levels of serum creatinine, while specific treatment is not necessary for asymptomatic patients with subnephrotic proteinuria.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213607

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  17 in total

1.  Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

2.  Comparative analysis of membranous and other nephropathy subtypes and establishment of a diagnostic model.

Authors:  Hanyu Zhu; Bo Fu; Yong Wang; Jing Gao; Qiuxia Han; Wenjia Geng; Xiaoli Yang; Guangyan Cai; Xiangmei Chen; Dong Zhang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

3.  Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

4.  Biomarker Identification in Membranous Nephropathy Using a Long Non-coding RNA-Mediated Competitive Endogenous RNA Network.

Authors:  Guangyu Zhou; Nan Jiang; Wenlong Zhang; Shuojie Guo; Guangda Xin
Journal:  Interdiscip Sci       Date:  2021-09-01       Impact factor: 2.233

5.  Long-term renal survival and related risk factors for primary membranous nephropathy in Chinese children: a retrospective analysis of 217 cases.

Authors:  Ren Wang; Meiqiu Wang; Zhengkun Xia; Chunlin Gao; Zhuo Shi; Xiang Fang; Heyan Wu; Yingchao Peng
Journal:  J Nephrol       Date:  2020-08-08       Impact factor: 3.902

6.  The clinicopathological features of patients with membranous nephropathy.

Authors:  Hanyu Zhu; Qiuxia Han; Dong Zhang; Yong Wang; Jing Gao; Xiaoli Yang; Wenjia Geng; Xiangmei Chen
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-01-18

7.  Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy.

Authors:  W Cui; X Lu; X Min; M Liu; S Guan; Y Wang; M Luo; W Li; Q Li; W Dong; L Miao; P Luo
Journal:  Braz J Med Biol Res       Date:  2017-03-23       Impact factor: 2.590

8.  Stepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathy.

Authors:  Dong Ho Shin; Mi Jung Lee; Hyung Jung Oh; Hyang Mo Koo; Fa Mee Doh; Hyoung Rae Kim; Jae Hyun Han; Jung Tak Park; Seung Hyeok Han; Kyu Hun Choi; Tae-Hyun Yoo; Shin-Wook Kang
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

9.  Integrated profiling of microRNA expression in membranous nephropathy using high-throughput sequencing technology.

Authors:  Wenbiao Chen; Xiaocong Lin; Jianrong Huang; Kuibi Tan; Yuyu Chen; Wujian Peng; Wuxian Li; Yong Dai
Journal:  Int J Mol Med       Date:  2013-11-12       Impact factor: 4.101

10.  miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy.

Authors:  Jing Li; Bin Liu; Hen Xue; Qiao Qiao Zhou; Ling Peng
Journal:  Biomed Res Int       Date:  2017-10-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.